About the study

This study will evaluate the safety, tolerability, pharmacokinetics, and activity of XmAb24306 in combination with a multiple myeloma (MM)-targeting monoclonal antibody capable of inducing antibody-dependent cellular toxicity (ADCC) in participants with relapsed or refractory (R/R) MM who have received a minimum of three prior treatments, including at least one immunomodulatory drug (IMiD), one proteasome inhibitor (PI), and one anti-CD38 monoclonal antibody.

Who can take part?

You may be eligible to participate in the study if you meet the following criteria:

Inclusion criteria

1. Life expectancy of at least 12 weeks
2. Measurable disease, as defined by the protocol
3. Participants must have received a minimum of 3 prior lines of therapy, including at least one PI, one IMiD, and an anti-CD38 monoclonal antibody
4. Best response of stable disease or better with at least one prior anti-CD38 monoclonal antibody containing line of treatment

Exclusion criteria

1. Any anti-cancer therapy within 3 weeks prior to initiation of study treatment, with exceptions defined by the protocol
2. Prior allogeneic stem cell or solid organ transplantation
3. Autologous stem cell transplantation within 100 days prior to initiation of study treatment
4. Significant cardiovascular disease
5. Known clinically significant liver disease
6. Active or history of autoimmune disease or immune deficiency
7. Known active infection requiring IV anti-microbial therapy within 14 days prior to first study drug administration
8. Primary or secondary plasma cell leukemia
9. Current CNS involvement by MM
10. Other protocol defined inclusion/exclusion criteria may apply

For a full list of inclusion/exclusion criteria, please visit ClinicalTrials.gov

Study locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.